Company Filing History:
Years Active: 2011
Title: Eilish Cullen: Innovator in Recombinant Technology
Introduction
Eilish Cullen is a prominent inventor based in London, GB. She has made significant contributions to the field of recombinant technology, particularly in the development of novel therapeutic compounds. Her innovative work has the potential to impact various medical applications.
Latest Patents
Eilish Cullen holds 1 patent related to a novel purified recombinant αβ adhesion receptor. This invention demonstrates unimpaired ligand binding activity and outlines a process for preparing the soluble, non-membrane bound receptor using recombinant techniques with a baculovirus-insect cell expression system. The synthesized soluble receptor serves as an effective screening tool for new therapeutic compounds that may inhibit the natural αβ adhesion receptor. Potential therapeutic compounds identified through this invention include RGD peptides and non-peptidic compounds that mimic natural ligand epitopes.
Career Highlights
Eilish Cullen is currently associated with Merck Patent GmbH, where she continues to advance her research and development efforts. Her work is characterized by a commitment to innovation and excellence in the field of biotechnology.
Collaborations
Eilish has collaborated with notable colleagues, including Simon Lawrence Goodman and Beate Diefenbach. These partnerships have further enriched her research and contributed to the success of her projects.
Conclusion
Eilish Cullen's contributions to recombinant technology exemplify her dedication to innovation in the medical field. Her work not only enhances our understanding of therapeutic compounds but also paves the way for future advancements in biotechnology.